The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?

Major Depressive Disorder Clinical Trial

— ECTAug  

Official title:

Memantine Augmentation of Electroconvulsive Therapy in Patients With Major Depression

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00988663
• Other study ID #: Memantine ECT trial
• Status: Withdrawn
• Phase: N/A
• First received: October 1, 2009
• Last updated: March 21, 2017
• Start date: November 2009
• Est. completion date: November 2009

Study information

• Verified date: March 2017
• Source: University of Iowa
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether memantine will enhance the therapeutic of effect on depression and prevent memory and other cognitive problems caused by ECT.

Description:

Patients will be assigned randomly either to a treatment group or a placebo groups. All patients in both groups will be receiving standard ECT. The treatment group will receive memantine. All patients will be given a battery of cognitive tests and test of depression before ECT treatments start, after the 6th ECT treatment and after the completions of ECT. An analysis will be performed to see if memantine causes any impact on the response to ECT and prevents memory and cognitive impairment.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 2009
• Est. primary completion date: November 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Meets criteria for Major Depressive disorder

Exclusion Criteria:

• Neurological disease

• Mental retardation

• Seizure disorder

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Drug:
• memantine
patient will receive 5mg daily for 7day then 10 mgm daily
• Placebo
will give placebo that looks like memantine

Locations

Country	Name	City	State
United States	University of Iowa hosptitals and clinic	Iowa City	Iowa

Sponsors (1)

Lead Sponsor	Collaborator
Jerrry L Lewis

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of whether Memantine protects memory and cognitive impairment caused by ECT.		6 to 8 weeks
Secondary	Whether memantine will improve response of Depression to Electroconvulsive therapy.		6-8 weeks